← Leaderboards
Kristie A Blum
Ohio State University
$3,505,109
Attributed
$8,387,680
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–19$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$8,387,680 · 5
By mechanism
U10$5,386,370 · 1
K24$886,297 · 1
R01$764,633 · 1
K23$675,380 · 1
R21$675,000 · 1
Top collaborators
- Arnab Chakravarti4 shared
- David E Cohn4 shared
- Michelle J. Naughton4 shared
- John C Byrd2 shared
- Rosa Lapalombella2 shared
- Claire F Verschraegen2 shared
- Jennifer A. Woyach2 shared
- Clara D Bloomfield1 shared
Most similar at Ohio State University
Same institution · by research overlap
- Claire F Verschraegen$7,194,564
- David P Carbone$20,647,321
- David Michael O'Malley$1,562,108
- William E. Carson$27,905,247
- Michael R Grever$17,739,693
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsToxic EffectRituximabResponseRefractoryTrainingGrantResearch PersonnelFundingUniversitiesClinical ResearchProgramsOhioLenalidomideNovel TherapeuticsBasePhase 1 StudyEvaluationDesignMutationB Lymphoid MalignancyS LymphomaRelapseCombined Modality Therapy
Grant awards (18)
Development of a comprehensive research program in mantle cell lymphoma in the ibrutinib era$174,691
K24 · FY2019 · CA · contact PI
OSU as Network Lead Academic Participating Site for the NCI NCTN$1,311,684
U10 · FY2018 · CA
Development of a comprehensive research program in mantle cell lymphoma in the ibrutinib era$176,011
K24 · FY2018 · CA · contact PI
OSU as Network Lead Academic Participating Site for the NCI NCTN$1,307,073
U10 · FY2017 · CA
Development of a comprehensive research program in mantle cell lymphoma in the ibrutinib era$177,298
K24 · FY2017 · CA · contact PI
OSU as Network Lead Academic Participating Site for the NCI NCTN$1,384,556
U10 · FY2016 · CA
Dual targeting of XPO1 and BTK in B cell malignancies$445,083
R01 · FY2016 · CA
Development of a comprehensive research program in mantle cell lymphoma in the ibrutinib era$178,543
K24 · FY2016 · CA · contact PI
OSU as Network Lead Academic Participating Site for the NCI NCTN$1,383,057
U10 · FY2015 · CA
Dual targeting of XPO1 and BTK in B cell malignancies$319,550
R01 · FY2015 · CA
Development of a comprehensive research program in mantle cell lymphoma in the ibrutinib era$179,754
K24 · FY2015 · CA · contact PI
Modulating the tumor micro-environment in CLL using flavopiridol and lenalidomide$337,500
R21 · FY2009 · CA · contact PI
Targeting Transcriptional Repression in CLL$135,076
K23 · FY2009 · CA · contact PI
Modulating the tumor micro-environment in CLL using flavopiridol and lenalidomide$337,500
R21 · FY2008 · CA · contact PI
Targeting Transcriptional Repression in CLL$135,076
K23 · FY2008 · CA · contact PI
Targeting Transcriptional Repression in CLL$135,076
K23 · FY2007 · CA · contact PI
Targeting Transcriptional Repression in CLL$135,076
K23 · FY2006 · CA · contact PI
Targeting Transcriptional Repression in CLL$135,076
K23 · FY2005 · CA